Sarepta Therapeutics to Present Additional 48-Week Data From the Phase IIb Study of Eteplirsen for Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics (NASDAQ: SRPT) announced today that data from a Phase IIb study evaluating eteplirsen, an investigational treatment for boys with Duchenne muscular dystrophy (DMD), will be presented Saturday, October 13th at the World Muscle Society in Perth, Australia. Principal investigator, Jerry R. Mendell, M.D. of Nationwide Children's Hospital, will present the data in an oral presentation of the abstract titled, "Results at 48 Weeks of a Phase IIb Extension Study of the Exon-Skipping Drug Eteplirsen in Patients with Duchenne muscular dystrophy (DMD)." Dr. Mendell will present tomorrow from 2:30 to 4:00 p.m. WST UTC +8 hours/2:30 to 4:00 a.m. EDT.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.